Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
High drop-out rate leads to the conclusion: not enough data will be available to perform proper analyses of data collected after follow-up month 24 visit
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Approximately 60 specialised clinics and 420 office based gynaecologists or oncologists will participate in this in practice evaluation program (NIS). The clinic and approximately 7 office based physicians will collaborate within their breast centre networks to conduct this program. A breast centre network should be able to recruit in this program approximately 80 patients (approximately 40 patients per year). It is planned to enroll approximately 4674 patients in this NIS (2337 patients per arm). The patient population will include postmenopausal women with hormone-receptor positive primary breast cancer scheduled for upfront adjuvant endocrine treatment with anastrozole according to the current standard medical procedures.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Standard routine care for breast cancer |
| |
| 2 | Standard + Intervention arm: standard routine care for breast cancer and additional information material via post |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anastrozole | Drug | oral |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Compliance rate and persistence rate | until discontinuation of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Time to treatment discontinuation | date of last intake of anastrozole minus date of first prescription of anastrozole + 1 | |
| Demographics and other baseline characteristics as well as information regarding concomitant medication, quality of life | until treatment discontinuation |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Postmenopausal women with hormone receptor positive primary breast cancer scheduled for upfront adjuvant endocrine treatment with anastrozole according to the current standard medical practice
Not provided
| Name | Affiliation | Role |
|---|---|---|
| AstraZeneca Germany Medical Director | AstraZeneca | Study Director |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23378537 | Derived | Hadji P, Blettner M, Harbeck N, Jackisch C, Luck HJ, Windemuth-Kieselbach C, Zaun S, Kreienberg R. The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer. Ann Oncol. 2013 Jun;24(6):1505-12. doi: 10.1093/annonc/mds653. Epub 2013 Feb 1. |
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D010349 | Patient Compliance |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077384 | Anastrozole |
| ID | Term |
|---|---|
| D009570 | Nitriles |
| D009930 | Organic Chemicals |
| D014230 | Triazoles |
| D001393 | Azoles |
| D006573 |
Not provided
Not provided
Not provided
Not provided
Not provided
| The percentage number of patients with disease free survival | after 12 months |
| Time of disease free survival | date of recurrence or progression of the tumor minus date of primary breast cancer surgery + 1 |
| D017437 |
| Skin and Connective Tissue Diseases |
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |